

The Economic Impact of Indwelling Urinary Catheterization on Total Joint Arthroplasty Procedures and Implications for Urinary Catheter Alternatives: A Systematic Review, Analysis, and Model

Timothy Kelly, MS, MBA;¹ Jun Li, PhD;² Mutsuo Yamazaki, PhD;³ Hiroshi Kubo, MD, PhD³
¹Becton Dickinson and Company (BD), Franklin Lakes, NJ, USA ; ²Becton Dickinson Asia, Ltd., Beijing, China; ³Nippon Becton Dickinson Company, Ltd., Tokyo, Japan

ISPOR 2025
May 13-16, 2025
Code: EE412

Background

Indwelling urinary catheters (IUCs) are commonly employed with patients undergoing total knee arthroplasty (TKA) and total hip arthroplasty (THA) procedures.¹ IUCs increase the risk of postoperative urinary tract infections (UTIs),² which in turn, increase the risk of prosthetic joint infections (PJIs).³ The use of intermittent straight catheters (ISCs) as alternatives to IUCs has been suggested to be beneficial in selected populations.⁴ With recent advances in less invasive alternatives, including external urinary catheters for both female and male patients,^{5,6} providers may benefit from estimating the potential reduction in UTIs that may result from avoidance of IUCs, and potentially from avoidance of ISCs, along with estimating the economic consequences of minimizing both UTI and PJI infections.

Objectives

Estimate the per-patient cost avoidance that may be realized by replacing IUCs with either ISCs, or no transurethral catheter of any type, in total joint arthroscopy patients. Estimate the per-patient cost avoidance achieved by reducing PJIs in TKA and THA patients through elimination of IUCs and ISCs.

Methods


A systematic review of original research and meta-analyses published from 2000-2025 (PubMed) was conducted to assess the impact of transurethral urinary catheters upon the adverse effects associated with TKA and THA procedures. The results were analyzed and applied to a model to estimate the UTI and PJI economic burden avoided when patients are managed without IUCs and ISCs.

Results

42 records were identified. After exclusions, 34 records were reviewed, and 7 were analyzed (Figure 1 and Table 1). The rate of postoperative UTI in patients managed with IUCs ranged from 1.8% to 6.2% across 6 studies,^{1,2,7,8,9,10} from 2% to 7.2% in patients managed with ISCs across 2 studies,^{2,10} and from 0% to 3.4% in patients managed without any type of transurethral catheters in 5 studies.^{2,7,8,9,10} One study² reported on the incidence of PJI: 2.9%, 1.3%, and 1.1% in patients managed with IUCs, with ISCs, and with no transurethral catheters, respectively.

The mean reductions in UTI incidence observed with avoiding IUCs and ISCs (2.5% and 1.9%, respectively) were multiplied by the cost for CAUTI and non-CAUTI hospital onset UTIs¹² (Table 2). That resulted in an estimated per patient UTI cost avoidance of \$245 (1,776 CNY; 36,750 JPY) when IUCs are eliminated and \$131 (950 CNY; 19,650 JPY) when ISCs are eliminated.

Figure 1: PRISMA Diagram



Results (contd.)

The per-case cost of a 2-stage revision for PJI was found by multiplying the revision rates for PJI occurring in TKA and THA¹³ by the cost of revisions for those procedures¹⁴ (Table 2). Those values were multiplied by the estimated PJI incidence reduction that would result from avoiding IUCs and ISCs (62% and 15%, respectively) yielding per-case PJI cost avoidance values ranging from \$18 (133 CNY; 2,755 JPY) when ISCs are avoided for TKA procedures to \$211 (1,527 CNY; 31,590 JPY) when IUCs are avoided for THA procedures.

Limitations

- Limitations of the model include but are not limited to: heterogeneity of the studies analyzed, applicability of the UTI costs cited to the actual cost of UTIs in the analyzed populations, paucity of studies on the revision rates due to PJI and per-case cost of PJI revisions, and applicability of the estimated PJI incidence reduction to the estimated revision reduction.
- It is unclear whether external urinary catheter alternatives would result in the same UTI rates reported in the various studies when no transurethral catheters (IUCs and ISCs) were used.

Conclusions


In most studies analyzed, IUCs were associated with higher postoperative UTI rates than were observed with patients managed with ISCs or with no transurethral catheters of any type. Modeling suggests that avoidance of IUCs, and also avoidance of ISCs, may reduce the occurrence, and thus the per-patient costs, associated with UTIs and PJIs.

Table 1: Publication Analysis

First Author	Publication Year	N	Type of Procedure	Intervention	UTI Incidence				
					IUC	ISC	No Catheter	Incidence Reduction (IUC vs. No Cath)	Incidence Reduction (ISC vs. No Cath)
Shuai ⁷	2021	1,334	TKA	IUC vs. no catheter	Patients with an IUC had a 2.72 RR of UTI compared to patients with no catheter				
Thiengwittayaporn ⁸	2021	230	TKA	IUC vs. no catheter					
Weintraub ⁹	2023	388	TKA and THA	IUC vs. no catheter					
Miller ¹⁰	2013	200	THA	IUC vs. no catheter					
Bjerregaard ¹	2019	784	TKA and THA	IUC until first post-op morning	4.2%				
Garbarino (TKA) ²	2020	9,123	TKA	IUC vs. ISC vs. both IUC and ISC ⁱ	4.8%	2.0%	2.0%	2.8%	0.0%
Garbarino (THA) ¹¹	2020	3,834	THA	IUC vs. ISC vs. both IUC and ISC ⁱⁱ	6.2%	7.2%	3.4%	2.8%	3.8%
ⁱ A 5.6% UTI rate was observed in the 'both IUC and ISC' cohort ⁱⁱ A 6.8% UTI rate was observed in the 'both IUC and ISC' cohort ⁱⁱⁱ A 1.3% PJI rate was observed in the 'both IUC and ISC' cohort					Mean reductions in UTI incidence:				
					PJI Incidence				
					IUC	ISC	No Catheter	Percentage Incidence Reduction (No Cath vs. IUC)	Percentage Incidence Reduction (No Cath vs. ISC)
Garbarino (TKA) ²	2020	9,123	TKA	IUC vs. ISC vs. both IUC and ISC ⁱⁱⁱ	2.9%	1.3%	1.1%	62%	15%

Table 2: Cost Avoidance Model

Estimated UTI incidence reduction by avoiding use of:	Cost of hospital-onset UTI ¹²	UTI Cost Avoidance per Patient
ISC	1.9%	\$6,874 ^{iv} \$131 (950 CNY) ^{vi} (19,650 JPY) ^{vi}
IUC	2.5%	\$9,807 ^v \$245 (1,776 CNY) ^{vi} (36,750 JPY) ^{vi}
^{iv} Cost of a non-catheter-associated UTI (non-CAUTI) hospital-onset UTI ^v Cost of a CAUTI ^v Exchange Rates: \$1 USD = 7.25 CNY, \$1 USD = 150 JPY		
Mean 90-day revision rate for infection ¹³	TKA	THA
Cost of a 2-stage revision for PJI ¹⁴	\$122,425	\$113,226
Per case cost of PJI revision	\$122	\$340
Estimated PJI incidence reduction by avoiding use of:		
ISC	15%	\$18 (133 CNY) ^{vi} (2,755 JPY) ^{vi}
IUC	62%	\$76 (550 CNY) ^{vi} (11,386 JPY) ^{vi}
^{vi} Exchange Rates: \$1 USD = 7.25 CNY, \$1 USD = 150 JPY		



Disclosures and Funding

The authors are all employees of Becton Dickinson and Company, a manufacturer of indwelling, intermittent, and external urinary catheters. Reference reprints and poster printing costs were funded by Becton Dickinson and Company.

References

- ¹Bjerregaard LS, Homilius M, Bagi P, Hansen TB, Kehlet H. Indwelling urinary catheterisation may increase risk of complications in hip and knee arthroplasty. *Dan Med J*. 2019 Apr;66(4):A5538.
- ²Garbarino LJ, Gold PA, Anis HK, Sodhi N, Danoff JR, Boraiah S, Rasquinha VJ, Mont MA. Does Intermittent Catheterization Compared to Indwelling Catheterization Decrease the Risk of Periprosthetic Joint Infection Following Total Knee Arthroplasty? *J Arthroplasty*. 2020 Jun;35(6S):S308-S312.
- ³Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. *Clin Orthop Relat Res*. 2008 Jul;466(7):1710-5.
- ⁴Centers for Disease Control and Prevention. Evidence Review. Guideline for Prevention of Catheter-Associated Urinary Tract Infections (2009). <https://www.cdc.gov/infection-control/hcp/cauti/evidence-review.html>. Updated: 4/12/24. Accessed: 4/24/25.
- ⁵Pryor N, Wang J, Young J, et al. Clinical outcomes of female external urine wicking devices as alternatives to indwelling catheters: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol*. 2024 May 6;45(9):1-9.
- ⁶Wagg A, Redmond DR. A Comparative Randomized Cross-Over Trial to Examine Efficacy of Urine Capture and Comfort of Two Male External Urine Collection Devices in Healthy Male Volunteers. *J Wound Ostomy Continence Nurs*. 2024 Nov-Dec 01;51(6):486-490.
- ⁷Shuai M, Li Y. Indwelling catheter increases the risk of urinary tract infection in total knee arthroplasty: A meta-analysis of randomized controlled trials. *Medicine (Baltimore)*. 2021 Apr 16;100(15):e25490.
- ⁸Thiengwittayaporn S, Uthaitas P, Hongku N, Tunyasuwanakul R, Limphunudom P, Leelachiewchankul F. Indwelling urinary catheterization was unnecessary in non-drainage total knee arthroplasty: a randomized controlled trial. *Arch Orthop Trauma Surg*. 2021 Mar;141(3):469-476.
- ⁹Weintraub MT, Yang J, Nam D, et al. Short-Term Indwelling Foley Catheters Do Not Reduce the Risk of Postoperative Urinary Retention in Uncomplicated Primary THA and TKA: A Randomized Controlled Trial. *J Bone Joint Surg Am*. 2023 Feb 15;105(4):312-9.
- ¹⁰Miller AG, McKenzie J, Greenky M, et al. Spinal anesthesia: should everyone receive a urinary catheter?: a randomized, prospective study of patients undergoing total hip arthroplasty. *J Bone Joint Surg Am*. 2013 Aug 21;95(16):1498-503.
- ¹¹Garbarino LJ, Gold PA, Anis H, et al. The Effect of Bladder Catheterization Technique on Postoperative Urinary Tract Infections After Primary Total Hip Arthroplasty. *J Arthroplasty*. 2020 Jun;35(6S):S325-S329.
- ¹²Kelly T, Ai C, Jung M, Yu K. Catheter-associated urinary tract infections (CAUTIs) and non-CAUTI hospital-onset urinary tract infections: Relative burden, cost, outcomes and related hospital-onset bacteremia and fungemia infections. *Infect Control Hosp Epidemiol*. 2024 Jul;45(7):864-871.
- ¹³Jin X, Gallego Luxan B, et al. Estimating incidence rates of periprosthetic joint infection after hip and knee arthroplasty for osteoarthritis using linked registry and administrative health data. *Bone Joint J*. 2022 Sep;104-B(9):1060-1066.
- ¹⁴Hammat AS, Nelson R, Davis JS, et al. Estimation of two-year hospital costs of hip and knee periprosthetic joint infection treatments using activity-based costing. *Bone Joint J*. 2024 Oct 1;106-B(10):1084-1092.